Lexicon Pharmaceuticals/$LXRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Ticker
$LXRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
103
ISIN
US5288723027
Website
LXRX Metrics
BasicAdvanced
$271M
-
-$0.51
1.08
-
Price and volume
Market cap
$271M
Beta
1.08
52-week high
$2.45
52-week low
$0.28
Average daily volume
3.9M
Financial strength
Current ratio
2.783
Quick ratio
2.783
Long term debt to equity
51.339
Total debt to equity
81.848
Interest coverage (TTM)
-13.25%
Profitability
EBITDA (TTM)
-164.64
Gross margin (TTM)
-172.09%
Net profit margin (TTM)
-568.04%
Operating margin (TTM)
-529.15%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-28.88%
Return on equity (TTM)
-86.09%
Valuation
Price to revenue (TTM)
8.341
Price to book
2.19
Price to tangible book (TTM)
3.45
Price to free cash flow (TTM)
-1.545
Free cash flow yield (TTM)
-64.71%
Free cash flow per share (TTM)
-48.24%
Growth
Revenue change (TTM)
1,251.21%
Earnings per share change (TTM)
-38.30%
3-year revenue growth (CAGR)
366.22%
10-year revenue growth (CAGR)
2.51%
3-year earnings per share growth (CAGR)
-6.12%
10-year earnings per share growth (CAGR)
-7.95%
What the Analysts think about LXRX
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
LXRX Financial Performance
Revenues and expenses
LXRX Earnings Performance
Company profitability
LXRX News
AllArticlesVideos
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewsWire·2 days ago
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·3 weeks ago
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $271M as of June 20, 2025.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of June 20, 2025.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.